Regulus Therapeutics Inc.: Revision history

20 August 2022

• curprev 15:2015:20, 20 August 2022 95.149.241.133 talk 760 bytes +11 No edit summary undo

13 August 2022

• curprev 23:1723:17, 13 August 2022 109.180.50.163 talk 749 bytes +15 No edit summary undo

8 August 2022

• curprev 02:5602:56, 8 August 2022 >Paris 734 bytes +734 Created page with "Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of aut..."